Search results for "Antidiuretic Agents"

showing 4 items of 4 documents

Desmopressin in the Treatment of Nocturia: A Double-Blind, Placebo-Controlled Study

2007

Objectives: To investigate efficacy, safety, and impact on quality of sleep of desmopressin in the treatment of nocturia. Methods: Adults aged >= 18 yr with nocturia (>= 2 voids/night) received desmopressin tablets (0.1, 0.2, or 0.4 mg) during a 3-wk dose-titration period. Patients should show sufficient response during the dose-titration period (>= 20% reduction in nocturnal diuresis) and a return of nocturnal diuresis to >= 80% of baseline levels during washout. Eligible patients then entered a 3-wk double-blind treatment period and received either desmopressin or placebo. Results: 127 patients were randomised to either desmopressin (n = 61) or placebo (n = 66). Twenty (33%) desmopressin-…

AdultMaleNephrologymedicine.medical_specialtyUrologyPlacebo-controlled studyAdministration OralDiuresisPlaceboDouble-Blind MethodInternal medicinemedicineHumansNocturiaDeamino Arginine VasopressinDesmopressinAdverse effectAgedAged 80 and overDose-Response Relationship Drugbusiness.industryAntidiuretic AgentsMiddle AgedSurgeryUrodynamicsTreatment OutcomeAnesthesiaFemaleNocturiamedicine.symptomSleepbusinesshormones hormone substitutes and hormone antagonistsFollow-Up Studiesmedicine.drugAntidiureticEuropean Urology
researchProduct

Desmopresssin and hemodilution: implications in doping.

2009

Blood doping improves physical performance in sport. This is the reason why the antidop- ing authorities subject athletes to blood tests. Plasma volume expanders are prohibited agents used to reduce an artifi cial increase in hemato- logical values using diff erent illegal practices. The aim of our study was to test whether desmo- pressin (DDAVP)-induced hemodilution would alter the concentration of hematological param- eters used to detect blood doping in sports. This was an intra-subject crossover study. Venous blood samples were obtained from eight physi- cally active males on two occasions. On the fi rst o ccasion the subjects ingested 1.5 L of mineral water and 4.3 μ g / kg of DDAVP. O…

AdultMalemedicine.medical_specialtyPhysical Therapy Sports Therapy and RehabilitationHematocritchemistry.chemical_compoundHemoglobinsYoung AdultBlood dopingInternal medicinemedicineHumansOrthopedics and Sports MedicineDeamino Arginine VasopressinDesmopressinDoping in SportsCreatinineHemodilutionCross-Over Studiesmedicine.diagnostic_testbusiness.industryAntidiuretic AgentsAlbuminVenous bloodCrossover studySubstance Abuse DetectionEndocrinologychemistryHematocritHemoglobinbusinessmedicine.drugSportsInternational journal of sports medicine
researchProduct

A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis

2012

Abstract Context Nocturia is a common urologic symptom that has been covered in a variety of reported studies in the literature but is not specifically covered in current guidelines. Objective To comprehensively review the literature pertaining to the definition, etiologies, and consequences of nocturia and assess the evidence supporting the use of conservative medical and interventional therapy. Evidence acquisition A literature search was conducted using the keyword nocturia , restricted to articles in the English language, after 2000 and before April 2012, in PubMed/Medline, Embase, Scopus, Web of Science, and Cochrane Library databases. Regarding treatment modalities, studies were inclu…

MaledesmopressinPathologyAnti-Inflammatory AgentsCochrane Libraryurologic and male genital diseaseslaw.inventionsystematic reviewRandomized controlled trialRisk FactorslawEpidemiologyOdds RatioPrevalencea1-blockersDesmopressina1-blockers; alpha(1)-blockers; antimuscarinics; desmopressin; meta-analysis; nocturia; nocturnal polyuria; systematic review; α1-blockersEvidence-Based MedicineAntidiuretic AgentsDiagnostic Techniques UrologicalMiddle AgedPathophysiologyfemale genital diseases and pregnancy complicationsTreatment OutcomeMeta-analysisUrologic Surgical ProceduresFemaleNocturiaα1-blockersmedicine.symptommedicine.drugmedicine.medical_specialtyUrologyMEDLINEMuscarinic Antagonistsalpha(1)-blockersPredictive Value of TestsInternal medicinemedicineHumansNocturiaIntensive care medicineantimuscarinicsAgedChi-Square Distributionbusiness.industrynocturnal polyuriaEvidence-based medicinemeta-analysisClinical trialUrodynamicsEndocrinologyAdrenergic alpha-1 Receptor AntagonistsbusinessEuropean urology
researchProduct

Lower Urinary Tract Symptoms: What's New in Medical Treatment?

2018

Abstract Context Pharmacological treatment is a cornerstone in the management of patients with lower urinary tract symptoms (LUTS). Objective To review emerging evidence in the medical treatment of LUTS. Evidence acquisition An Embase/Pubmed-based literature search was conducted in December 2017, screening for randomized controlled trials (RCTs), prospective and retrospective series, animal model studies, and reviews on medical treatment of LUTS. Evidence synthesis The main medical innovation in recent years in overactive bladder (OAB) has been the approval of the first β 3 -adrenoceptor agonists (mirabegron) and intradetrusor onabotulinum toxin A, while several other drugs such as antiepil…

Malemedicine.medical_specialtyReceptors VasopressinUrologyUrinary Bladder030232 urology & nephrologyUrologyProstatic HyperplasiaUrinary incontinenceAdrenergic beta-3 Receptor Agonistsurologic and male genital diseases03 medical and health sciences0302 clinical medicineLower Urinary Tract SymptomsLower urinary tract symptomsmedicineDesmopressin AcetateNocturiaHumansDeamino Arginine VasopressinProspective StudiesBotulinum Toxins Type ADesmopressinRandomized Controlled Trials as TopicRetrospective StudiesUrinary bladderbusiness.industryUrinary Bladder OveractiveAntidiuretic AgentsPhosphodiesterase 5 Inhibitorsmedicine.diseasefemale genital diseases and pregnancy complicationsThiazolesmedicine.anatomical_structureOveractive bladderClinical Trials Phase III as Topic030220 oncology & carcinogenesisModels AnimalAcetanilidesFemaleNocturiamedicine.symptomMirabegronbusinessmedicine.drugEuropean urology focus
researchProduct